J&J, Vertex Partner To Commercialize VX-950 For Hepatitis C
J&J gains rights to the protease inhibitor in certain international markets with a $165 mil. up-front payment to Vertex.
J&J gains rights to the protease inhibitor in certain international markets with a $165 mil. up-front payment to Vertex.